Loan-Thy Dang, MD
Family Medicine · Honolulu, HINPI 1891923108
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,680 and has fallen 97.6% since, to $40 in 2025.
Across 207 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$420
- Gilead$411
- Novo Nordisk$340
- AbbVie$293
- Amgen$285
- Amarin Pharma, Inc.$246
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,481100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $420 |
| Gilead | 17 | $411 |
| Novo Nordisk | 23 | $340 |
| AbbVie(2 entities) | 19 | $293 |
| Amgen | 15 | $285 |
| Amarin Pharma, Inc. | 17 | $246 |
| GSK | 13 | $204 |
| Merck | 14 | $203 |
| Lilly USA, LLC | 7 | $122 |
| Boehringer Ingelheim | 6 | $108 |
| Novartis | 6 | $96 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Pfizer | 4 | $57 |
| Redhill Biopharma Inc. | 3 | $53 |
| Dynavax Technologies Corporation | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $30 |
| Corcept Therapeutics | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Abbott | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
| Vivus LLC | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Phadia US Inc. | 1 | $15 |
| Althera Pharmaceuticals LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Mission Pharmacal Company | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,481 in reported general payments places this provider in the 85th percentile of 376 family medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 137 | $212,642 |
| RybelsusSemaglutide | 85 | $207,185 |
| JanuviaSitagliptin Phosphate | 113 | $161,099 |
| OzempicSemaglutide | 47 | $97,899 |
| EliquisApixaban | 45 | $73,441 |
| InvokanaCanagliflozin | 23 | $41,877 |
| MounjaroTirzepatide | 15 | $39,522 |
| Atorvastatin Calcium | 1,174 | $38,729 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $25,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $21,616 |
| TrulicityDulaglutide | 13 | $20,032 |
| CreonLipase/Protease/Amylase | 11 | $19,513 |
| VascepaIcosapent Ethyl | 19 | $16,455 |
| Losartan Potassium | 630 | $10,826 |
| Rosuvastatin Calcium | 183 | $9,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $340 | $305,085132 claims |
| Boehringer IngelheimJardiance | $108 | $212,642137 claims |
| MerckJanuvia | $203 | $161,099113 claims |
| PfizerEliquis | $57 | $73,44145 claims |
| Lilly USA, LLCMounjaro, Trulicity | $122 | $59,55428 claims |
| Johnson & JohnsonInvokana | $17 | $41,87723 claims |
| AbbVieCreon, Synthroid | $293 | $23,36679 claims |
| GSKTrelegy Ellipta | $204 | $21,61619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 376 family medicine providers in Hawaii.
Other family medicine in Honolulu
- Vicente RamoHonolulu$34K
- Choon YeoHonolulu$20K
- Gavino VinzonsHonolulu$15K
- Thuy-Linh NguyenHonolulu$9K
- Owen NishikawaHonolulu$7K
- Kelsey FinnHonolulu$5K
- Curtis Takemoto GentileHonolulu$4K
- Krishanna Takemoto-GentileHonolulu$4K
- Yoichi SomaHonolulu$4K
- Ronnie OtienoHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.